Synthetic Vaccine Particles (SVP™) are targeted to interact with immune cells and induce antigen-specific immune responses. SVP are compatible with a wide range of antigens and immunomodulators. The broad applicability and manufacturing scalability that we have demonstrated with our SVP technology platform continues to enable us to engage in collaborations with leading industry organizations.
For further information about Selecta and the company’s collaboration opportunities, please contact email@example.com.
Selecta is collaborating with the Duke University Medical Center on the potential to utilize SVP-Rapamycin to reduce the immunogenicity of biologic treatments for Pompe disease, which impacts approximately one in 12,000-40,000 people in the United States.
Genethon is providing adeno-associated virus (AAV)-based gene therapies and animal models to enable the use of SVP products to mitigate the formation of anti-drug antibodies and to enable repeat administration in gene therapy.
The International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy is teaming with Selecta on an SVP-enabled gene therapy candidate for the treatment of Ornithine Transcarbamylase Deficiency (OTC), an inborn error of metabolism affecting approximately one in 15,000-60,000 newborns in the United States.
Selecta has in-licensed Anc80, an in silico designed gene therapy vector, from Massachusetts Eye and Ear for the treatment of several diseases, including Methylmalonic Acidemia (MMA), an inborn error of metabolism affecting approximately one in 25,000-48,000 newborns in the United States.
Selecta is collaborating with the National Cancer Institute (NCI) on the development of a combination product candidate consisting of LMB-100 and SVP-Rapamycin, known as Selecta’s SEL-403 product candidate, as a potential treatment for pancreatic cancer, mesothelioma and other cancers.
Selecta is teaming with the Venditti laboratory at the National Human Genome Research Institute (NHGRI) on an SVP-enabled gene therapy candidate for the treatment of Melthylmalonic Acidemia (MMA), a rare inborn error of metabolism.
In 2014, Selecta Biosciences was awarded an $8.1 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH), to support research into the development of a next-generation vaccine for smoking cessation and relapse prevention.
The Skolkovo Foundation has committed up to $2.7 million in research funding to support Selecta’s development of an immunostimulatory therapeutic SVP to treat human papilloma virus-associated cancers by stimulating the immune system.